Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

por Subbiah, Vivek, Cassier, Philippe A., Siena, Salvatore, Garralda, Elena, Paz-Ares, Luis, Garrido, Pilar, Nadal, Ernest, Vuky, Jacqueline, Lopes, Gilberto, Kalemkerian, Gregory P., Bowles, Daniel W., Seetharam, Mahesh, Chang, Jianhua, Zhang, Hui, Green, Jennifer, Zalutskaya, Alena, Schuler, Martin, Fan, Yun, Curigliano, Giuseppe
Publicado 2022

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic

por Kamoun, Walid, Swindell, Elden, Pien, Christine, Luus, Lia, Cain, Jason, Pham, Minh, Kandela, Irawati, Huang, Zhaohua Richard, Tipparaju, Suresh K., Koshkaryev, Alexander, Askoxylakis, Vasileios, Kirpotin, Dmitri B., Bloom, Troy, Mino-Kenudson, Mari, Marks, James D., Zalutskaya, Alena, Bshara, Wiam, Morrison, Carl, Drummond, Daryl C.
Publicado 2020

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

por Eno, Meredith S., Brubaker, Jason D., Campbell, John E., De Savi, Chris, Guzi, Timothy J., Williams, Brett D., Wilson, Douglas, Wilson, Kevin, Brooijmans, Natasja, Kim, Joseph, Özen, Ayşegül, Perola, Emanuele, Hsieh, John, Brown, Victoria, Fetalvero, Kristina, Garner, Andrew, Zhang, Zhuo, Stevison, Faith, Woessner, Rich, Singh, Jatinder, Timsit, Yoav, Kinkema, Caitlin, Medendorp, Clare, Lee, Christopher, Albayya, Faris, Zalutskaya, Alena, Schalm, Stefanie, Dineen, Thomas A.
Publicado 2022